Eledon Pharmaceuticals Announces Presentation at the American Society of Nephrology Kidney Week 2026 Annual MeetingGlobeNewsWire · Oct 5, 2026
Eledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation SocietyGlobeNewsWire · Sep 22, 2026
Eledon Pharmaceuticals Announces Presentation at the International Congress of The Transplantation SocietyGlobeNewsWire · Sep 9, 2026
Eledon Pharmaceuticals Announces Islet Cell Transplantation IND Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial in Fourth Quarter 2026GlobeNewsWire · Sep 3, 2026
647,812 Shares in Eledon Pharmaceuticals, Inc. $ELDN Acquired by ADAR1 Capital Management LLCDefense World · Aug 26, 2026
Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business HighlightsGlobeNewsWire · Aug 13, 2026Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating innovative treatments for individuals battling autoimmune disorders, amyotrophic lateral sclerosis (ALS), and those undergoing organ or cell transplantation. Their flagship therapeutic candidate, AT-1501, is a humanized monoclonal antibody engineered to specifically target CD40 Ligand, a crucial protein found on the surface of immune system T cells. This compound is currently undergoing Phase 2a clinical studies for ALS treatment and Phase 2 trials for islet cell transplantation, aiming to address type 1 diabetes.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | -$0.16 | -$0.27 | Miss |
| May 13, 2026 | -$0.22 | -$0.33 | Miss |
| Mar 19, 2026 | -$0.20 | -$0.10 | Beat |
| Nov 14, 2025 | -$0.22 | -$0.21 | Beat |
| Aug 14, 2025 | -$0.23 | -$0.13 | Beat |
| May 14, 2025 | -$0.28 | -$0.08 | Beat |